Cited by 29Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchBioinformatics and Genomic Networks

Bridging the gap: Multi‐omics profiling of brain tissue in Alzheimer's disease and older controls in multi‐ethnic populations

Open access
Reddy, Joseph S., Heath, Laura, Linden, Abby Vander, Allen, Mariet, Lopes, Katia de Paiva, Seifar, Fatemeh, Wang, Erming, Ma, Yiyi +45 more·2024·Alzheimer's & Dementia

Published version of a preprint

Abstract

INTRODUCTION: Multi‐omics studies in Alzheimer's disease (AD) revealed many potential disease pathways and therapeutic targets. Despite their promise of precision medicine, these studies lacked Black Americans (BA) and Latin Americans (LA), who are disproportionately affected by AD. METHODS: To bridge this gap, Accelerating Medicines Partnership in Alzheimer's Disease (AMP‐AD) expanded brain multi‐omics profiling to multi‐ethnic donors. RESULTS: We generated multi‐omics data and curated and harmonized phenotypic data from BA ( n = 306), LA ( n = 326), or BA and LA ( n = 4) brain donors plus non‐Hispanic White ( n = 252) and other ( n = 20) ethnic groups, to establish a foundational dataset enriched for BA and LA participants. This study describes the data available to the research community, including transcriptome from three brain regions, whole genome sequence, and proteome measures. DISCUSSION: The inclusion of traditionally underrepresented groups in multi‐omics studies is essential to discovering the full spectrum of precision medicine targets that will be pertinent to all populations affected with AD. Highlights: Accelerating Medicines Partnership in Alzheimer's Disease Diversity Initiative led brain tissue profiling in multi‐ethnic populations. Brain multi‐omics data is generated from Black American, Latin American, and non‐Hispanic White donors. RNA, whole genome sequencing and tandem mass tag proteomicsis completed and shared. Multiple brain regions including caudate, temporal and dorsolateral prefrontal cortex were profiled.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/alz.14208

Cites

100 of 101 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Large-scale studies such as ROS/MAP have used multi-omic data from dorsolateral prefrontal cortex tissue to identify Alzheimer's disease subtypes that exhibit distinct cognitive trajectories.

    “Large-scale studies such as ROS/MAP project have utilized multi-omic data from dorsolateral prefrontal cortex tissue to identify AD subtypes that exhibit distinct cognitive trajectories.”

    From Artificial intelligence-driven multi-omics approaches in Alzheimer's disease: Progress, challenges, and future directions (2025) · cites this paper as [397]

    The Methods and Results sections identify ROS/MAP as a contributing cohort and describe multi-omics profiling of dorsolateral prefrontal cortex tissue. The paper does not report using those data to identify Alzheimer’s disease subtypes with distinct cognitive trajectories (searched: subtypes, cognitive trajectories). (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • Deep learning frameworks have uncovered novel biological pathways, including those related to neuroinflammation and metabolic regulation, which account for diverse disease trajectories.

    “Deep learning frameworks continue to uncover novel biological pathways, including those related to neuroinflammation and metabolic regulation, which account for diverse disease trajectories397,398.”

    From Artificial intelligence-driven multi-omics approaches in Alzheimer's disease: Progress, challenges, and future directions (2025) · cites this paper as [397]

    The Discussion (page not provided) says multi-omics data revealed alterations in pathways including innate immunity and mitochondrial energetics, supporting heterogeneous molecular etiologies. It does not attribute those findings to deep learning frameworks or establish that the pathways account for diverse disease trajectories. (LLM, conf=0.84)

    Experimental — accuracy not yet measured
  • Alzheimer's disease subtypes identified from ROS/MAP differ in lipid metabolism and synaptic function.

    “These subtypes differ in lipid metabolism and synaptic function, highlighting the utility of combining molecular and clinical data to capture disease heterogeneity124,255,396,397.”

    From Artificial intelligence-driven multi-omics approaches in Alzheimer's disease: Progress, challenges, and future directions (2025) · cites this paper as [397]

    The Study populations section identifies ROS and MAP as cohorts, and the Discussion mentions heterogeneous molecular changes, including synaptic biology. Neither passage reports ROS/MAP Alzheimer’s subtypes or differences between them in lipid metabolism and synaptic function. Searches for “subtypes,” “lipid metabolism,” and “synaptic function” found no passage addressing those differences; page numbers were unavailable in our copy. (LLM, conf=0.76)

    Experimental — accuracy not yet measured
  • Reviews of multi-omics analyses in brain tissue have emphasized the importance of time-series data in capturing the dynamic evolution of molecular and clinical features.

    “Reviews of multi-omics analyses in brain tissue have emphasized the importance of time-series data in capturing the dynamic evolution of molecular and clinical features397.”

    From Artificial intelligence-driven multi-omics approaches in Alzheimer's disease: Progress, challenges, and future directions (2025) · cites this paper as [397]

    The Discussion (page unavailable) emphasizes sampling multiple brain regions because regions are affected at different disease stages. It does not discuss the importance of time-series data for capturing evolving molecular and clinical features; searches for time-series data and longitudinal dynamics found no such passage. (LLM, conf=0.76)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Reddy, J. S., Heath, L., Linden, A. V., Allen, M., Lopes, K. D. P., Seifar, F., Wang, E., Ma, Y., Poehlman, W. L., Quicksall, Z. S., Runnels, A., Wang, Y., Duong, D. M., Yin, L., Xu, K., Modeste, E. S., Shantaraman, A., Dammer, E. B., Ping, L., Oatman, S. R., Scanlan, J., Ho, C., Carrasquillo, M. M., Atik, M., Yepez, G., Mitchell, A. O., Nguyen, T. T., Chen, X., Marquez, D. X., Reddy, H., Xiao, H., Seshadri, S., Mayeux, R., Prokop, S., Lee, E. B., Serrano, G. E., Beach, T. G., Teich, A. F., Haroutunian, V., Fox, E. J., Gearing, M., Wingo, A., Wingo, T., Lah, J. J., Levey, A. I., Dickson, D. W., Barnes, L. L., De Jager, P., Zhang, B., Bennett, D., Seyfried, N. T., Greenwood, A. K., & Ertekin‐Taner, N.
Affiliations
  • Mayo Clinic in Florida (US)
  • Sage Bionetworks (US)
  • Rush Alzheimer's Disease Center Rush University Medical Center Chicago Illinois USA
  • Emory University (US)
  • Icahn School of Medicine at Mount Sinai (US)
  • Columbia University Irving Medical Center (US)
  • New York Genome Center (US)
  • Rush University Medical Center (US)
  • Mayo Clinic Florida Jacksonville Florida USA
  • The University of Texas at San Antonio (US)
  • University of Florida (US)
  • University of Pennsylvania (US)
  • Banner Sun Health Research Institute (US)
  • Columbia University Irving Medical Center New York New York USA
Corresponding author
  • Greenwood, Anna K.
  • Ertekin‐Taner, Nilüfer
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2024-08-30
Volume
20
Issue
10
Pages
7174-7192
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
OpenAlex
W4402094108
Cited by
29
References
101
Citations by year
2026: 9 · 2025: 14 · 2024: 6
FWCI
8.25
Type
journal article
Language
en
Open access
Locations
  • Alzheimer s & Dementia (publishedVersion, cc-by-nc-nd)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by-nc-nd)
  • PubMed Central (submittedVersion, cc-by-nc-nd)
Funders
  • National Institute on Aging (P50 AG016574, R01 AG032990, U01 AG046139, R01 AG018023, U01 AG006576, U01 AG006786, R01 AG025711, R01 AG017216, R01 AG003949, P30AG072979, P01AG066597, U19AG062418, U01AG061357, RF1AG062181, P30AG066511)
  • Mayo Foundation for Medical Education and Research
  • National Institute of Neurological Disorders and Stroke (R01‐NS080820)
  • Arizona Department of Health Services
  • Arizona Biomedical Research Commission
  • Michael J. Fox Foundation for Parkinson's Research
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
Keywords
Alzheimer's disease, multi-omics profiling

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review